Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review

Bipolar androgen therapy (BAT) is a new endocrinologic treatment for castration-resistant prostate cancer (CRPC) that can restore some patients’ sensitivity to drugs such as abiraterone (Abi) and enzalutamide (Enz). We performed a meta-analysis using STATA16. Sensitivity analyses were performed by e...

Descripción completa

Detalles Bibliográficos
Autores principales: You, Xiangyun, Huang, Shan, Wang, Xin’an, Yi, Cheng, Gong, Niandong, Yu, Junfeng, Xu, Chengdang, Xiang, Zhendong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10127253/
https://www.ncbi.nlm.nih.gov/pubmed/37113653
http://dx.doi.org/10.3389/fendo.2022.1125838

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10127253/
https://www.ncbi.nlm.nih.gov/pubmed/37113653
http://dx.doi.org/10.3389/fendo.2022.1125838

Ejemplares similares